• Debt reduction plan: The company is raising ₹150 crore in fresh primary proceeds to lower its net debt of roughly ₹380 crore, while relying on over ₹200 crore in annual operational cash accruals to fund future needs.
• Growth engine expansion: Following more than ₹800 crore in CAPEX over recent years, the company is expanding from its core $1 billion steroid and hormone API segment into multi-billion-dollar complex injectables and large-scale fermentation CDMO markets.
• Promoter share sale: Management clarified that the promoter's partial share sale in the IPO is solely aimed at clearing debt taken on to participate in the previous rights issue priced at ₹276 per share.
• Revenue mix diversification: Although APIs currently generate 96% of sales and the top five products account for 62% of revenue, management expects contribution from complex injectables and CDMO to rise significantly starting next fiscal year.